查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1598799

尿路上皮癌治療藥物市場：按藥物類型、治療類型、分銷管道和最終用戶分類 - 全球預測 2025-2030

Urothelial Cancer Drugs Market by Drug Type (Avelumab, Cisplatin, Doxorubicin), Treatment Type (Chemotherapy, Immunotherapy), Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年尿路上皮癌治療市值為31.6億美元，預計2024年將達34.7億美元，複合年成長率為9.92%，到2030年將達到61億美元，預計將達到3000萬美元。

尿路上皮癌治療涵蓋了一系列由其在治療膀胱、輸尿管和腎盂內壁尿路上皮細胞中產生的癌症中的重要作用所定義的範圍。膀胱癌盛行率的不斷上升推動了市場需求，這需要先進的治療方案。應用包括免疫療法、化療和旨在減緩疾病進展的標靶治療。最終用途主要包括醫院、癌症研究中心和使用這些藥物的專業診所。根據市場開拓洞察，老年人口增加、創新藥物開發以及製藥公司之間的聯盟等主要成長要素正在推動市場擴張。此外，精準醫學和生物標記主導療法的出現為實現針對性和有效治療提供了潛在機會。為了抓住這些機會，我們建議投資研究和合作夥伴關係，以開發突破性新藥，並最佳化藥品價格以實現更廣泛的使用。然而，治療成本上漲、嚴格的監管核准以及導致患者不願意的潛在副作用等挑戰正在阻礙市場成長。發展中地區的專業醫療保健設施也有限。為了克服這些問題，市場相關人員應專注於降低製造成本和加強監管途徑。創新治療領域包括組合藥物療法的開發、改進的藥物傳輸系統以及利用人工智慧進行個人化治療。此外，正在進行的對尿路上皮癌的遺傳和表觀遺傳影響的研究可能會揭示新的治療標靶。尿路上皮癌藥物市場是一個充滿活力的市場，既有成熟的治療方法，也有新的創新治療方法。成功需要領先於不斷發展的研究趨勢，解決成本障礙，並確保採用以患者為中心的藥物開發方法。未滿足的醫療需求和科學進步之間的平衡為開發下一代療法提供了肥沃的土壤，這些療法有望帶來更好的患者結果和商業性潛力。

主要市場統計
基準年[2023] 31.6億美元
預測年份 [2024] 34.7億美元
預測年份 [2030] 61.3億美元
複合年成長率（%） 9.92%

市場動態：揭示快速發展的尿路上皮癌藥物市場的關鍵市場洞察

供需的動態交互作用正在改變尿路上皮癌藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 吸煙習慣導致膀胱癌患者增加
    • 越來越重視免疫治療和標靶治療
    • 政府積極治療癌症
  • 市場限制因素
    • 尿路上皮癌治療藥物對健康的不良影響
  • 市場機會
    • 新型尿路上皮癌治療的監管核准數量迅速增加
    • 膀胱癌研究活動不斷取得進展
  • 市場挑戰
    • 對功效和毒性的擔憂

波特五力：駕馭尿路上皮癌藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解尿路上皮癌藥物市場的外部影響

外部宏觀環境因素在塑造尿路上皮癌治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解尿路上皮癌治療藥物市場的競爭狀況

尿路上皮癌治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣尿路上皮癌治療市場供應商的績效評估

FPNV定位矩陣是評估尿路上皮癌治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪尿路上皮癌治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對尿路上皮癌治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 吸煙習慣導致膀胱癌發生率增加
      • 免疫療法和標靶治療將變得更加重要
      • 政府首選的癌症治療方法
    • 抑制因素
      • 尿路上皮癌藥物對健康的不良影響
    • 機會
      • 尿路上皮癌治療的新監管核准激增
      • 膀胱癌研究工作不斷取得進展
    • 任務
      • 對功效和毒性的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第 6 章：按藥物類型分類的尿路上皮癌治療市場

  • Avelumab
  • Cisplatin
  • 阿黴素
  • 恩福單抗維多汀
  • 厄達非替尼
  • 納多法拉根菲拉德諾維克-VNCG
  • 沙珠單抗戈維替康

第7章依治療類型分類的尿路上皮癌治療藥物市場

  • 化療
  • 免疫療法

第8章尿路上皮癌治療藥物市場：按分銷管道

  • 離線
  • 線上

第9章尿路上皮癌治療市場：依最終用戶分類

  • 門診手術中心
  • 居家護理設施
  • 醫院/診所

第10章北美及南美尿路上皮癌治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區尿路上皮癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的尿路上皮癌藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Actiza Pharmaceutical Pvt. Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca
  • Bedford Pharmaceuticals by Hikma Pharmaceuticals PLC
  • Bristol Myers Squibb
  • Cygnus Healthcare Specialities Pvt. Ltd.
  • Eisai Co., Ltd.
  • Emcure Pharmaceuticals
  • F. Hoffmann-La Roche AG
  • Ferring Group
  • Getwell Oncology
  • GlaxoSmithKline PLC
  • Hetero Drugs Ltd.
  • Hikma Pharmaceuticals PLC
  • Janssen Pharmaceuticals by Johnson & Johnson Services, Inc.
  • Lexicare Pharma Private Limited
  • Manus Aktteva Biopharma LLP
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Salvavidas Pharmaceutical Pvt. Ltd.
  • Sanofi SA
  • Taj Pharmaceuticals Limited
  • Trumac Healthcare
  • UroGen Pharma
Product Code: MRR-521BAA36EBB8

The Urothelial Cancer Drugs Market was valued at USD 3.16 billion in 2023, expected to reach USD 3.47 billion in 2024, and is projected to grow at a CAGR of 9.92%, to USD 6.13 billion by 2030.

Urothelial cancer drugs encompass a scope defined by their essential role in treating cancer that originates in the urothelial cells lining the bladder, ureter, and renal pelvis. The market necessity stems from the increasing incidence of bladder cancer, necessitating advanced therapeutic options. Applications include immunotherapy, chemotherapy, and targeted therapies designed to curb disease progression. End-use primarily involves hospitals, cancer research centers, and specialty clinics administering these drugs. Market insights reveal key growth factors like the rising geriatric population, innovative drug development, and collaborations between pharmaceutical companies propelling market expansion. Additionally, the advent of precision medicine and biomarker-driven therapies presents a potential opportunity for targeted and effective treatments. The recommendations to seize these opportunities involve investing in research and partnerships leading to breakthrough drugs and optimizing drug prices for broader accessibility. However, market growth is challenged by factors such as high treatment costs, stringent regulatory approvals, and potential side effects leading to patient reluctance. There's also a limited availability of specialized healthcare facilities in developing regions. To overcome these, market players should focus on reducing production costs and enhancing regulatory pathways. Innovation areas ripe for exploration include the development of combinatorial drug therapies, improving drug delivery systems, and harnessing artificial intelligence for personalized treatment regimens. Additionally, ongoing research into genetic and epigenetic influences on urothelial cancer can unlock novel therapeutic targets. The urothelial cancer drug market is dynamic, with a blend of mature therapies and emerging innovations. Successful navigation requires staying ahead of evolving research trends, addressing cost barriers, and ensuring patient-centric approaches to drug development. The balance of unmet medical needs with scientific advancement provides a fertile ground for developing next-generation therapies promising better patient outcomes and commercial viability.

KEY MARKET STATISTICS
Base Year [2023] USD 3.16 billion
Estimated Year [2024] USD 3.47 billion
Forecast Year [2030] USD 6.13 billion
CAGR (%) 9.92%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Urothelial Cancer Drugs Market

The Urothelial Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising cases of bladder cancer due to smoking habits
    • Increasing emphasis on immunotherapy and targeted theraphy
    • Favorable government initiatives for cancer treatment
  • Market Restraints
    • Adverse health impacts of urothelial cancer drugs
  • Market Opportunities
    • Surging regulatory approvals for novel urothelial cancer drugs
    • Ongoing advancements in bladder cancer research activities
  • Market Challenges
    • Concern associated with drug efficacy and toxicity

Porter's Five Forces: A Strategic Tool for Navigating the Urothelial Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Urothelial Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Urothelial Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Urothelial Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Urothelial Cancer Drugs Market

A detailed market share analysis in the Urothelial Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Urothelial Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Urothelial Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Urothelial Cancer Drugs Market

A strategic analysis of the Urothelial Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Urothelial Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Actiza Pharmaceutical Pvt. Ltd., Astellas Pharma Inc., AstraZeneca, Bedford Pharmaceuticals by Hikma Pharmaceuticals PLC, Bristol Myers Squibb, Cygnus Healthcare Specialities Pvt. Ltd., Eisai Co., Ltd., Emcure Pharmaceuticals, F. Hoffmann-La Roche AG, Ferring Group, Getwell Oncology, GlaxoSmithKline PLC, Hetero Drugs Ltd., Hikma Pharmaceuticals PLC, Janssen Pharmaceuticals by Johnson & Johnson Services, Inc., Lexicare Pharma Private Limited, Manus Aktteva Biopharma LLP, Merck & Co., Inc., Novartis AG, Pfizer Inc., Salvavidas Pharmaceutical Pvt. Ltd., Sanofi S.A., Taj Pharmaceuticals Limited, Trumac Healthcare, and UroGen Pharma.

Market Segmentation & Coverage

This research report categorizes the Urothelial Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Avelumab, Cisplatin, Doxorubicin, Enfortumab Vedotin, Erdafitinib, Nadofaragene Firadenovec-vncg, and Sacituzumab Govitecan.
  • Based on Treatment Type, market is studied across Chemotherapy and Immunotherapy.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Home Care Facilities, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising cases of bladder cancer due to smoking habits
      • 5.1.1.2. Increasing emphasis on immunotherapy and targeted theraphy
      • 5.1.1.3. Favorable government initiatives for cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse health impacts of urothelial cancer drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Surging regulatory approvals for novel urothelial cancer drugs
      • 5.1.3.2. Ongoing advancements in bladder cancer research activities
    • 5.1.4. Challenges
      • 5.1.4.1. Concern associated with drug efficacy and toxicity
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Urothelial Cancer Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Avelumab
  • 6.3. Cisplatin
  • 6.4. Doxorubicin
  • 6.5. Enfortumab Vedotin
  • 6.6. Erdafitinib
  • 6.7. Nadofaragene Firadenovec-vncg
  • 6.8. Sacituzumab Govitecan

7. Urothelial Cancer Drugs Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Immunotherapy

8. Urothelial Cancer Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
  • 8.3. Online

9. Urothelial Cancer Drugs Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Home Care Facilities
  • 9.4. Hospitals & Clinics

10. Americas Urothelial Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Urothelial Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Urothelial Cancer Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Actiza Pharmaceutical Pvt. Ltd.
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca
  • 4. Bedford Pharmaceuticals by Hikma Pharmaceuticals PLC
  • 5. Bristol Myers Squibb
  • 6. Cygnus Healthcare Specialities Pvt. Ltd.
  • 7. Eisai Co., Ltd.
  • 8. Emcure Pharmaceuticals
  • 9. F. Hoffmann-La Roche AG
  • 10. Ferring Group
  • 11. Getwell Oncology
  • 12. GlaxoSmithKline PLC
  • 13. Hetero Drugs Ltd.
  • 14. Hikma Pharmaceuticals PLC
  • 15. Janssen Pharmaceuticals by Johnson & Johnson Services, Inc.
  • 16. Lexicare Pharma Private Limited
  • 17. Manus Aktteva Biopharma LLP
  • 18. Merck & Co., Inc.
  • 19. Novartis AG
  • 20. Pfizer Inc.
  • 21. Salvavidas Pharmaceutical Pvt. Ltd.
  • 22. Sanofi S.A.
  • 23. Taj Pharmaceuticals Limited
  • 24. Trumac Healthcare
  • 25. UroGen Pharma

LIST OF FIGURES

  • FIGURE 1. UROTHELIAL CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. UROTHELIAL CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UROTHELIAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. UROTHELIAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. UROTHELIAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. UROTHELIAL CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY CISPLATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY DOXORUBICIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ENFORTUMAB VEDOTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ERDAFITINIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NADOFARAGENE FIRADENOVEC-VNCG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY SACITUZUMAB GOVITECAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. UROTHELIAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. UROTHELIAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023